Abstract Designing positron emission tomography (PET) tracers for targets in the central nervous system (CNS) is challenging. Besides showing high affinity and high selectivity for their intended target, these tracers have to be able to cross the blood-brain barrier (BBB). Since only a small fraction of small molecules is estimated to be able to cross the BBB, tools that can predict permeability at an early stage during the development are of great importance. One such tool is in silico models for predicting BBB-permeability. Thus far, such models have been built based on CNS drugs, with one exception. Herein, we sought to discuss and analyze if in silico predictions that have been built based on CNS drugs can be applied for CNS PET tracer...
In order to reach their pharmacologic targets, successful central nervous system (CNS) drug candidat...
Inappropriate pharmacokinetic has been recognized as being one of the major factors leading to the w...
The aim of the present study was to identify a model for the blood-brain barrier based on the use of...
International audienceThe development of effective central nervous system (CNS) drugs has been hampe...
The blood–brain barrier (BBB) is a microvascular unit which selectively regulates the permeability o...
Predicting blood-brain barrier (BBB) permeability is essential to drug development, as a molecule ca...
This article is available online at http://dmd.aspetjournals.org ABSTRACT: The objectives of this st...
The penetration of drugs into the central nervous system is a composite of both the rate of drug upt...
Permeability assessment of small molecules through the blood-brain barrier (BBB) plays a significant...
The treatment of brain disorders is limited by the insufficiency in delivering therapeutic drugs int...
AbstractThe blood-brain barrier (BBB) is formed by specialized tight junctions between endothelial c...
Background: Development of tracers for imaging with positron emission tomography (PET) is often a ti...
The permeation of drugs across the blood-brain barrier (BBB) is a prerequisite for central nervous s...
In order to reach their pharmacologic targets, successful central nervous system (CNS) drug candidat...
Inappropriate pharmacokinetic has been recognized as being one of the major factors leading to the w...
The aim of the present study was to identify a model for the blood-brain barrier based on the use of...
International audienceThe development of effective central nervous system (CNS) drugs has been hampe...
The blood–brain barrier (BBB) is a microvascular unit which selectively regulates the permeability o...
Predicting blood-brain barrier (BBB) permeability is essential to drug development, as a molecule ca...
This article is available online at http://dmd.aspetjournals.org ABSTRACT: The objectives of this st...
The penetration of drugs into the central nervous system is a composite of both the rate of drug upt...
Permeability assessment of small molecules through the blood-brain barrier (BBB) plays a significant...
The treatment of brain disorders is limited by the insufficiency in delivering therapeutic drugs int...
AbstractThe blood-brain barrier (BBB) is formed by specialized tight junctions between endothelial c...
Background: Development of tracers for imaging with positron emission tomography (PET) is often a ti...
The permeation of drugs across the blood-brain barrier (BBB) is a prerequisite for central nervous s...
In order to reach their pharmacologic targets, successful central nervous system (CNS) drug candidat...
Inappropriate pharmacokinetic has been recognized as being one of the major factors leading to the w...
The aim of the present study was to identify a model for the blood-brain barrier based on the use of...